as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹1,501.6
Change
+46.6 (3.2%)
Open
₹1,451.0
Prev. Close
₹1,455.0
Day High
₹1,527.7
Day Low
₹1,431.0
Volume Analysis
Traded
42,678
Delivered
23,091
Delivery %
54.11%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (57.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,639.24 | ₹1,583.47 | ₹1,542.54 | ₹1,486.77 | ₹1,445.84 | ₹1,390.07 | ₹1,349.14 |
| Fibonacci | ₹1,583.47 | ₹1,546.53 | ₹1,523.71 | ₹1,486.77 | ₹1,449.83 | ₹1,427.01 | ₹1,390.07 |
| Camarilla | ₹1,528.19 | ₹1,519.33 | ₹1,510.46 | ₹1,486.77 | ₹1,492.74 | ₹1,483.87 | ₹1,475.01 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+97.45%
1 Week
+3.95%
1 Month
-0.81%
3 Months
-13.61%
6 Months
+38.77%
1 Year
+117.91%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹954.9
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
15.79%
Net margin 14.58% × asset turnover 0.91x × equity multiplier 1.19x
Company Overview
Sector
Healthcare
Market Cap
₹2,002 Cr
P/E (TTM)
16.4
ROE
15.6%
Book Value
₹527.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Venus Remedies Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Liquidity (49/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (21.0%). Strong 3-year EPS growth (57.0%).
TopFund Score — Fundamentals Quality
70/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has delivered good profit growth of 20.0% CAGR over last 5 years
- +Company's working capital requirements have reduced from 88.6 days to 61.9 days
- −Stock is trading at 2.84 times its book value
- −The company has delivered a poor sales growth of 7.09% over past five years.
- −Company has a low return on equity of 9.53% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Shared social media links for special window to re-lodge physical share transfer requests.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 | 219 |
| Expenses + | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 | 176 |
| Operating Profit | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 | 42 |
| OPM % | 11.0% | 8.0% | 10.0% | 10.0% | 4.5% | 10.0% | 15.0% | 11.0% | 16.0% | 21.0% | 24.0% | 19.0% | 19.0% |
| Other Income + | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 | 10 |
| Profit before tax | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 | 33 |
| Tax % | 31.0% | 12.0% | 40.0% | 82.0% | 61.0% | 21.0% | 32.0% | 24.0% | 24.0% | 24.0% | 23.0% | 24.0% | 23.0% |
| Net Profit + | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 | 26 |
| EPS in Rs | 7 | 5 | 8 | 1 | 3 | 15 | 16 | 7 | 15 | 19 | 36 | 17 | 19 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 20 | 23 | 25 | 14 | 1 | 23 | 0 | 26 | 13 | 2 | 33 | 30 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 645 | 766 | 837 |
| Expenses + | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 619 | 660 |
| Operating Profit | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 69 | 147 | 178 |
| OPM % | 20.0% | 20.0% | 13.0% | 11.0% | 10.0% | 12.0% | 10.0% | 10.0% | 11.0% | 10.0% | 11.0% | 19.0% | 21.0% |
| Other Income + | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 26 | 13 | 11 |
| Interest | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 26 | 30 |
| Profit before tax | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 134 | 159 |
| Tax % | -95.0% | 52.0% | -21.0% | 11.0% | -4.0% | 24.0% | -27.0% | -12.0% | 30.0% | 36.0% | 37.0% | 23.0% | — |
| Net Profit + | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 103 | 122 |
| EPS in Rs | 5 | 1 | -14 | -25 | -23 | -8 | 50 | 30 | 20 | 21 | 34 | 77 | 91 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.0% | — |
| Sales growth | -14 | -11 | -2 | -7 | -14 | 4 | 62 | 10 | -8 | 8 | 8 | 19 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 445 | 426 | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 650 | 691 |
| Borrowings + | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 12 | 12 |
| Other Liabilities + | 64 | 70 | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 178 | 123 |
| Total Liabilities | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 | 840 |
| Fixed Assets + | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 232 | 217 |
| CWIP | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 51 | 75 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 238 | 240 |
| Other Assets + | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 333 | 307 |
| Total Assets | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 854 | 840 |
| Equity Capital | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 13 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 68 | 47 | 59 | 31 | 45 | 78 | 132 | 41 | 37 | 37 | 86 | 156 |
| Cash from Investing Activity + | -67 | 3 | -18 | 8 | -11 | -5 | 57 | -17 | -58 | -8 | -77 | -185 |
| Cash from Financing Activity + | -1 | -46 | -44 | -39 | -35 | -73 | -162 | -9 | -1 | -1 | -1 | -3 |
| Net Cash Flow | -1 | 3 | -4 | 0 | -1 | 0 | 27 | 14 | -22 | 28 | 9 | -32 |
| Free Cash Flow | 59 | 46 | 41 | 19 | 35 | 70 | 132 | 41 | 29 | 24 | 69 | 118 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 76 | 58 | 116 | 79 | 139 | 190 | 245 | 66 | 61 | 89 | 148 | 129 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 56.65% | 56.76% | 57.17% | 57.06% | 57.13% | 56.9% | 55.89% | 55.62% | 54.95% | 54.24% | 54.44% | 54.37% |
| Promoters | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| FII | 1.59% | 1.48% | 1.06% | 1.18% | 1.11% | 1.34% | 2.25% | 1.86% | 2.25% | 2.8% | 2.92% | 3.14% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.11% | 0.75% | 1.03% | 1.2% | 0.89% | 0.74% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Venus Remedies Limited (this stock) | 2,002 | 16.4 | 2.84 | 15.6% |
| Hester Biosciences Ltd | 1,992 | 33.9 | 4.26 | 15.9% |
| Beta Drugs Limited | 1,990 | 38.3 | 4.54 | 18.8% |
| Windlas Biotech Limited | 2,067 | 31.1 | 3.64 | 12.2% |
| Indoco Remedies Ltd. | 2,079 | — | 2.03 | -9.36% |
| Syncom Formu (i) Ltd | 1,907 | 20.0 | 4.06 | 17.6% |
| Panacea Biotec Ltd | 2,171 | — | 2.6 | -2.42% |
Which Mutual Funds Hold Venus Remedies Limited?
Frequently Asked Questions about Venus Remedies Limited
Venus Remedies Limited (VENUSREM) closed at ₹1,501.6 on NSE on 19 November 2026, up 46.6 (3.2%) from the previous close.
Venus Remedies Limited trades on the NSE (National Stock Exchange of India) under the symbol VENUSREM.
Venus Remedies Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 16.4.
Venus Remedies Limited has a dividend yield of 0.67%.
Venus Remedies Limited's 52-week high is ₹2,044.0 and its 52-week low is ₹550.0.
Venus Remedies Limited has a market capitalisation of ₹2,002 crore.
Venus Remedies Limited has a TopFund Quality Score of 70/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Venus Remedies Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.